<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A cerebral metabolic activator was administered to patients with cerebrovascular <z:hpo ids='HP_0000726'>dementia</z:hpo> to treat <z:hpo ids='HP_0000020'>urinary incontinence</z:hpo> or <z:hpo ids='HP_0100515'>pollakisuria</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The results are of interest as discussed in this paper </plain></SENT>
<SENT sid="2" pm="."><plain>This study was carried out on 35 patients (15 males and 20 females) with cerebrovascular <z:hpo ids='HP_0000726'>dementia</z:hpo> with the chief complaint of <z:e sem="disease" ids="C0021167" disease_type="Disease or Syndrome" abbrv="">incontinence</z:e> or <z:hpo ids='HP_0100515'>pollakisuria</z:hpo> averaging in age 78.1 years with a range of 65 to 92 </plain></SENT>
<SENT sid="3" pm="."><plain>The underlying disease was <z:hpo ids='HP_0001342'>cerebral hemorrhage</z:hpo> in 4 cases, <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> in 21 cases and sequelae of <z:e sem="disease" ids="C0038454" disease_type="Disease or Syndrome" abbrv="">cerebral apoplexy</z:e> in 10 cases </plain></SENT>
<SENT sid="4" pm="."><plain>ADL was assessed in <z:hpo ids='HP_0000001'>all</z:hpo> cases by cerebral CT or MRI and Hasegawa's test, a simple test for <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Bladder function was evaluated by determining urodynamic tests (CMG, UFM, UPP) before and after medical treatment </plain></SENT>
<SENT sid="6" pm="."><plain>Test drug was bifemelane <z:chebi fb="16" ids="36807">hydrochloride</z:chebi>, a cerebrovascular metabolic activator </plain></SENT>
<SENT sid="7" pm="."><plain>It was administered at a dose of 150 mg/day for periods of 2 months or more </plain></SENT>
<SENT sid="8" pm="."><plain>As a result, bladder symptoms improved in 16/35 patients (45.7%), and mental symptoms in 21/35 (60%) </plain></SENT>
<SENT sid="9" pm="."><plain>Urine voiding and holding as bladder functions determined by urodynamics tests were not affected at <z:hpo ids='HP_0000001'>all</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>The effect of this drug on bladder symptoms is secondary to improvement of mental symptoms, and its most pronounced clinical effect was on <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
</text></document>